CRP at diagnosis in psoriatic arthritis: what it means and associations with long-term outcomes Authors: Angeliki E Dimopoulou, Charalampos Papagoras, Niki Kyriazi, Sousana Gazi, Evangelia Mole, Michael Krikelis, Paraskevi V Voulgari, Evripidis Kaltsonoudis, Nikolaos Koletsos, Pelagia Katsimpri, Dimitrios Boumpas, Dimitrios Katsifis-Nezis, Nikolaos Kougkas, Theodoros Dimitroulas, Petros P Sfikakis, Maria G Tektonidou, Konstantinos D Vassilakis, Dimitrios Bogdanos, Theodora Simopoulou, Christos Koutsianas, Eugenia Mavrea, Gkikas Katsifis, Konstantinos Kottas, Maria Konsta, Matthoula Tziafalia, Evangelia Kataxaki, Eleni Kalavri, Kalliopi Klavdianou, Anastasios Karamanakos, Ioannis Xynogalas, Dimitrios Daoussis, George Iliopoulos, Ilias Bournazos, Konstantinos Georganas, Dimos Patrikos, Dimitrios Vassilopoulos, George E Fragoulis Published: 2026 ABSTRACT AbstractObjectiveThe role of CRP in PsA as a diagnostic and prognostic marker is debated. We compared clinical and epidemiological features, as well as long-term outcomes, between patients with ‘elevated’ (>0.5 mg/dl) and patients with ‘normal’ (≤0.5 mg/dl) CRP at diagnosis.MethodsIn this real-world study, we analysed data from 609 PsA patients categorized by their CRP at diagnosis. Demographics, clinical characteristics, comorbidities, and long-term outcomes were compared. The statistically significant variables in the univariate analyses were used to build two multivariable logistic regression models: (i) assessing associations between CRP and features at PsA diagnosis and (ii) examining its link with long-term outcomes (including ‘difficult to manage’ and ‘persistent disease’) and characteristics throughout the disease course.ResultsOf 609 patients, 132 (21.7%) displayed normal and 477 (78.3%) elevated CRP values at diagnosis. By univariate analysis, elevated CRP was associated with longer disease follow-up, BMI of >25 kg/m2, enthesitis (at diagnosis and during the disease course), hypertension, hyperuricaemia, new bone formation, and ‘persistent disease’. By multivariable analyses, elevated CRP at diagnosis was independently linked with BMI of >25 kg/m2 [odds ratio (OR) 1.69, 95% CI 1.05–2.72], enthesitis (OR 2.04, 95% CI 1.24–3.38), hypertension (OR 2.07, 95% CI 1.04–4.11), new bone formation (OR 2.57, 95% CI 1.33–4.94) and ‘persistent disease’ (OR 4.36, 95% CI 2.22–8.59).ConclusionOverall PsA characteristics are comparable, irrespective of the CRP levels at diagnosis, apart from new bone formation, enthesitis, ‘persistent disease’ and increased cardiometabolic burden, which were independently associated with elevated CRP levels at PsA diagnosis.Keywords: CRP, psoriatic arthritis, long-term outcomes CRP has limited value for monitoring PsA activity but may help identify distinct disease phenotypes and predict long-term outcomes. CRP has limited value for monitoring PsA activity but may help identify distinct disease phenotypes and predict long-term outcomes. Elevated CRP at PsA diagnosis is associated with a persistent disease phenotype, enthesitis, new bone formation, and increased cardiometabolic burden. Elevated CRP at PsA diagnosis is associated with a persistent disease phenotype, enthesitis, new bone formation, and increased cardiometabolic burden. Introduction PsA is a complex, chronic, immune-mediated inflammatory disease involving multiple organ systems. Its multifaceted presentation consists of both musculoskeletal manifestations, such as peripheral arthritis, axial disease, dactylitis and enthesitis, and extra-musculoskeletal manifestations, including psoriasis, nail involvement, IBD, and eye involvement, most commonly uveitis [1, 2]. Additionally, a variety of associated comorbidities, such as cardiovascular disease, metabolic syndrome, mental health disorders, and FM, further augment PsA’s heterogeneity and burden [3–5]. Both genetic and environmental (especially intestinal microbiome and mechanical stress) factors have been implicated in the disease’s pathogenesis, with key roles being attributed to the IL-23/IL-17 pathway, TNF and IL-22 [1, 6, 7]. CRP is a pentraxin produced by hepatocytes in response to inflammatory proteins, such as IL-1β, IL-6 and TNF, that aids in complement binding and macrophage phagocytosis [8–10]. It is one of the most commonly used biomarkers of systemic inflammation and tissue injury, being highly sensitive, readily available, and cost-efficient [9, 11], and it is particularly suitable for recognizing and monitoring acute inflammatory states [10, 11]. However, caution should be exerted in interpretation of this acute-phase reactant’s levels—even though an increase can serve as confirmation of clinical suspicion of inflammation, it is not specific, and normal levels cannot be evidence enough to exclude it [9]. Given that this acute-phase reactant is found to be elevated in only about half of the patients with active PsA [12], a handful of studies have come out investigating its role in disease activity measurement in PsA. Within the PsA community, the most appropriate index for disease activity, evaluation, and treatment tailoring has long been debated, with the potential redundancy of CRP in routine evaluation being a concern [12–14]. The Disease Activity index for PSoriatic Arthritis (DAPSA) and its clinical variant (cDAPSA—which is calculated with the same parameters as the former, omitting CRP)—have been shown to result in similar patient categorization according to disease activity [13, 15, 16]. On the other hand, cDAPSA remission scores and Minimal Disease Activity (MDA) state have been documented as not being aligned with the indications of CRP levels [17]. In addition, in a study examining definitions of remission and low disease activity, proportions of patients with increased CRP were comparable across the definitions, so it was argued that CRP might not provide additional information in terms of monitoring [14]. Nevertheless, there are some data to support that CRP at diagnosis can serve as a predictor for adverse outcomes, including structural damage [11, 18–21]. Therefore, with this real-world nationwide study, we aimed to investigate whether CRP serum levels at diagnosis could be linked to different subgroups of PsA, with potentially different clinical and epidemiological features, and different disease courses. Methods Data was extracted from the Greek Rheumatology Society’s multicentre study [22] of PsA patients (fulfilling the CASPAR criteria). The data for all patients who visited the participating clinics and private practices between 1 January 2022 and 31 December 2022 (time of assessment) were analysed cross-sectionally. The protocol and data collected have been described in detail elsewhere [22]. In summary, in the original cohort, adult individuals (≥18 years) with PsA attending University Hospitals, National Health System Hospitals, or private practices across Greece were enrolled regardless of disease duration (newly diagnosed or established PsA) and irrespective of prior treatment exposure [conventional synthetic (cs)DMARD-treated, biologic (b)DMARD–naïve, bDMARD recipients, or targeted synthetic (ts)DMARD recipients]. Briefly, the following features were recorded: demographics (e.g. age and working status), time of follow-up (time between PsA diagnosis and the time of assessment), clinical and laboratory characteristics (e.g. joint counts, enthesitis, IBD, BSA), indices (e.g. DAPSA, HAQ) and comorbidities at the time of PsA diagnosis and thereafter. Past and present anti-rheumatic treatments, as well as last available (prior to time of assessment) hands and spine (including SI joints) imaging were recorded. For this project, we considered the cut-off for elevated and normal CRP to be 0.5 mg/dl. Accordingly, patients were categorized into a ‘normal’ (CRP ≤ 0.5 mg/dl) and an ‘elevated’ (CRP > 0.5 mg/dl) CRP group at the time of PsA diagnosis. A dichotomous categorization of patients was proposed, to allow for a more clinically applicable, efficient, and easily interpretable comparison. Univariate analyses were conducted examining the associations of elevated or normal CRP at diagnosis with demographics, comorbidities, disease characteristics at the time of PsA diagnosis and at any time during the disease course, as well as with long-term outcomes. The latter included radiographic damage (erosions and new bone formation on hand x-rays, sacroiliitis, and syndesmophytes on spine X-rays) and arthroplasties, as well as HAQ, difficult to manage (D2M) disease, and treatment refractory (TR) disease status based on data collected on the time of assessment. As per the recently published EULAR points for consideration [23], D2M was defined as evidence of ‘persistent disease’ [(a) not being in MDA and/or (b) having at least one active extra-musculoskeletal manifestation and/or (c) demonstrating ‘inflammatory activity’ (CRP > 0.5 mg/dl and/or positive findings in MRI in the 6 months prior to the time of assessment)] while having failed to achieve and maintain response with at least two b/tsDMARDs, with at least two mechanisms of action. According to the same definition, TR disease was defined as: having at least two of the ‘persistent disease’ characteristics (with ‘inflammatory activity’ being mandatory) and failure to achieve and maintain response with at least two b/tsDMARDs, with at least two mechanisms of action. Additionally, according to the TR definition, patients with co-morbidities, and psychosocial and other factors that can be considered drivers of ‘persistent disease’ should be excluded. For the purpose of this study, we viewed depression and neoplasia as such drivers. For the univariate analysis, categorical characteristics were compared using the Fisher’s exact test and numerical values with the unpaired t test for parametric variables, and the Mann–Whitney test for non-parametric variables. Normal distribution was checked with the Kolmogorov–Smirnov test. Two multivariable models (backward conditional models) were built, to examine the association of CRP at diagnosis with (i) characteristics at that time (first model) and with (ii) long-term outcomes, manifestations at any time during the disease course, and comorbidities (second model). The variables demonstrating statistical significance in the univariate analysis, as well as age and gender, were used as independent variables. It is important to stress that follow-up time was included in the second model. We acknowledge that the design of the second model does not conform to temporal sequencing. This model was constructed to explore associations between CRP at diagnosis and characteristics across the disease course, rather than causal relationships, and its results should be interpreted as such. Statistical significance for both the univariate and multivariable analyses was set at a P-value of <0.05. In the multivariable analyses, the results were expressed as odds ratios (ORs) along with 95% CIs. GraphPad Prism 5.00 (GraphPad Software, Inc., Boston, MA, USA) and SPSS 24.0 (SPSS software, Chicago, IL, USA) were used for the statistical analysis. Results Patient characteristics Of the 923 initially included patients, 609 had documented CRP levels at diagnosis. The mean ± s.d. age was 55.7 ± 12.6 years, 55.0% were females, and the mean ± s.d. follow-up time was 8.3 ± 7.2 years. Among the patients included, 132 (21.7%) displayed normal CRP levels at diagnosis and 477 (78.3%) displayed elevated CRP levels. It is of note that 80.3% of the patients in the ‘normal’ CRP group still demonstrated normal CRP at the time of assessment. Comparison between patients with normal and elevated CRP—univariate analyses Demographics and disease characteristics at PsA diagnosis Regarding the demographic characteristics (including age, gender and smoking), there were no differences between the two groups, apart from the follow-up time (80.9 ± 76.7 vs 105.2 ± 87.6 months, P = 0.004) and the percentage of patients with a BMI of >25 kg/m2 (65.1% vs 77.1%, P = 0.014), which were significantly longer and higher, respectively, in the ‘elevated’ CRP group (Supplementary Table S1). Along the same lines, among the disease characteristics at the time of diagnosis, only the frequency of enthesitis differed, being higher in the ‘elevated’ CRP group (22.0% vs 35.6%, P = 0.004) (Supplementary Table S1). Disease characteristics throughout the disease course and long-term outcomes Throughout the disease course, significantly more patients in the ‘elevated’ CRP group compared with the ‘normal’ group displayed enthesitis (55.1% vs 44.9%, P = 0.045), hypertension (48.7% vs 35.5%, P = 0.011), hyperuricaemia (21.3% vs 8.3%, P < 0.001) (Supplementary Table S2) and new bone formation (but not erosions) as seen in hand x-rays (60.1% vs 31.2%, P < 0.0001) (Table 1). The mean time between PsA diagnosis and the conducting of hand x-rays was 3.27 ± 5.32 years in the ‘elevated’ group and 1.79 ± 2.89 in the ‘normal’ group, with no statistically significant difference being found between the groups (P = 0.16). Table 1Comparison of long-term outcomes in patients included in this study. Long term outcomes a ‘Normal’ CRP at Dx (21.7%) (n = 132)‘Elevated’ CRP at Dx (78.3%) (n = 477) P-valueHand x-rays Erosion28/78 (35.9%)114/343 (33.2%)0.691 New bone formation24/77 (31.2%)206/343 (60.1%)0.0001Spine and SI joint x-raysAt least one positive XRb25/91 (40%)81/335 (28.4%)0.585 Sacroiliitisc9/80 (38.8%)45/307 (28.3%)0.587 Presence of syndesmophytes on spine18/50 (36.0%)51/220 (23.2%)0.073Arthroplasty7/132 (5.3%)11/477 (2.3%)0.083 Disease status at the time of assessment Not in MDA26/50 (52.0%)87/235 (37.0%)0.057Active EMMd64/132 (48.5%)285/477 (59.7%)0.022Inflammatory activitye33/132 (25.0%)242/477 (50.7%)0.0001Persistent diseasef79/132 (59.8%)382/477 (80.1%)0.0001D2M25/132 (18.9%)106/477 (22.2%)0.473TR4/132 (3.0%)26/477 (5.5%)0.363HAQ0.357 (0.610), n = 730.276 (0.383), n = 3590.156Numbers are N (%). aBased on the data available and collected at the time of assessment. bAt least one finding on x-rays consistent with sacroiliac involvement or spine involvement, as defined by syndesmophyte presence. c≥Grade 2. dHaving at least one active extra-musculoskeletal manifestation. eCRP > 0.5 mg/dl and/or positive findings in MRI (SI joints and spine wherever) in the 6 months prior to time of assessment. f(a) not being in MDA and/or (b) having at least one active extra-musculoskeletal manifestation, and/or (c) demonstrating ‘inflammatory activity’. D2M: difficult to manage; Dx: diagnosis; EMMs: extra-musculoskeletal manifestations; MDA: Minimal Disease Activity; TR: treatment refractory; XR: X-ray. Comparison of long-term outcomes in patients included in this study. Numbers are N (%). aBased on the data available and collected at the time of assessment. bAt least one finding on x-rays consistent with sacroiliac involvement or spine involvement, as defined by syndesmophyte presence. c≥Grade 2. dHaving at least one active extra-musculoskeletal manifestation. eCRP > 0.5 mg/dl and/or positive findings in MRI (SI joints and spine wherever) in the 6 months prior to time of assessment. f(a) not being in MDA and/or (b) having at least one active extra-musculoskeletal manifestation, and/or (c) demonstrating ‘inflammatory activity’. D2M: difficult to manage; Dx: diagnosis; EMMs: extra-musculoskeletal manifestations; MDA: Minimal Disease Activity; TR: treatment refractory; XR: X-ray. At the time of assessment, MDA was achieved at comparable percentages in the two groups, whereas ‘inflammatory activity’ (50.7% vs 25.0%, P = 0.0001) and at least one active extra-musculoskeletal manifestation (59.7% vs 48.5%, P = 0.022) were more common in the ‘elevated’ CRP group (Table 1). Overall, evidence of ‘persistent disease’ was documented with a higher frequency in the ‘elevated’ CRP group (80.1% vs 59.8%, P < 0.001), while D2M and TR status were not significantly different (Table 1). Treatment received at the time of the assessment, as well as median number of b/tsDMARDs failed was similar between the ‘elevated’ and ‘normal’ CRP groups (Supplementary Table S3). Comparison between patients with normal and ‘elevated’ CRP—multivariable analyses Two multivariable analyses were performed, both with CRP status at diagnosis as the dependent variable. In the first model (Table 2), BMI > 25 and enthesitis at the time of diagnosis retained their association with ‘elevated’ CRP [OR 1.69 (CI = 1.05–2.72) and 2.04 (CI = 1.24–3.38), respectively], after adjustment for age and gender. In the second model (Table 2), hypertension (HTN) (OR 2.07, CI = 1.04–4.11), new bone formation in hand x-rays (OR 2.57, CI = 1.33–4.94), and ‘persistent disease’ (OR 4.36, CI = 2.22–8.59), were found to be associated with ‘elevated’ CRP (Table 2). Table 2Multivariable analyses. Two different models that have the CRP at the time of diagnosis as a dependent variable.Characteristics at the time of diagnosis (Model 1) P-valueORCIBMI > 25 kg/m20.0301.6891.051–2.715Enthesitis0.0052.0441.237–3.375 Long term effects and characteristics ever displayed (Model 2) HTN0.0372.0701.044–4.105Hyperuricaemia0.0772.7780.894–8.632New bone formationa0.0052.5651.331–4.942Persistent diseaseb<0.0014.3642.216–8.594Variables entered on step 1 for characteristics at Dx: age, gender, BMI and enthesitis at Dx—variables entered on step 1 for long-term effects and characteristics ever displayed: age, gender, follow-up time in months, BMI, enthesitis ever displayed, HTN, hyperuricaemia, new bone formation, and persistent disease. aAs seen in hand x-rays. b(a) not being in MDA and/or (b) having at least one active extra-musculoskeletal manifestation and/or (c) demonstrating ‘inflammatory activity’ (CRP > 0.5 mg/dl and/or positive findings in MRI (SI joints and spine wherever) in the 6 months prior to time of assessment). Dx: diagnosis; HTN: hypertension; MDA: Minimal Disease Activity; OR: odds ratio. Multivariable analyses. Two different models that have the CRP at the time of diagnosis as a dependent variable. Variables entered on step 1 for characteristics at Dx: age, gender, BMI and enthesitis at Dx—variables entered on step 1 for long-term effects and characteristics ever displayed: age, gender, follow-up time in months, BMI, enthesitis ever displayed, HTN, hyperuricaemia, new bone formation, and persistent disease. aAs seen in hand x-rays. b(a) not being in MDA and/or (b) having at least one active extra-musculoskeletal manifestation and/or (c) demonstrating ‘inflammatory activity’ (CRP > 0.5 mg/dl and/or positive findings in MRI (SI joints and spine wherever) in the 6 months prior to time of assessment). Dx: diagnosis; HTN: hypertension; MDA: Minimal Disease Activity; OR: odds ratio. Discussion This study aimed to assess the potential association of CRP at the time of PsA diagnosis with long-term outcomes. We categorized the patients into two groups according to their CRP levels at diagnosis, ‘normal’ and ‘elevated’, in order to more efficiently explore potential associations that could be useful in clinical practice. In this large, real-life, contemporary patient cohort, elevated CRP at diagnosis was linked with a higher frequency of being overweight (BMI > 25) and having enthesitis at diagnosis, as well as with the development of HTN, new bone formation, and ‘persistent disease’ during follow-up. In our study, 21.7% of the enrolled patients displayed normal CRP at PsA diagnosis and 78.3% displayed elevated CRP. This stated prevalence of ∼20% of the enrolled patients having a normal CRP at diagnosis can be explained by the low cut-off value (CRP ≤ 0.5 mg/dl), as well as the heterogeneity of the study population and the diverse clinical settings. However, considering the different cut-offs used in the literature, this is in agreement with the findings of other investigators. In a study by Haroon et al. [11], 56.5% of 283 patients enrolled had elevated CRP at their first rheumatology visit, with the cut-off set at CRP > 10.0 mg/l. In a subanalysis of the ADEPT randomized controlled trial [19], the baseline CRP was <1.0 mg/dl in 60% of the 152 patients in the placebo group and in 66% of the 144 patients in the adalimumab group, whereas in a study by van der Heijde et al. [18], with the cut-off for elevated CRP set at 2.87 mg/l, normal baseline CRP was observed in 36.4% of the patients in the ‘tofacitinib 5 mg twice daily’ group, 36.5% in the ‘tofacitinib 10 mg twice daily’ and 39.6% in the ‘adalimumab’ group. Therefore, depending on the cut-off used, approximately half of PsA patients do not have increased CRP at the time of diagnosis. In our study, patients with elevated CRP at PsA diagnosis displayed a higher incidence of BMI > 25kg/m2. Obesity, an established PsA comorbidity, has been previously associated with elevated CRP levels in patients with PsA [11, 24]. It is considered that it mediates a low-grade inflammatory state due to the established endocrine and inflammatory properties of adipose tissue, which, among other tissues, secretes cytokines such as IL-6 and TNFα, subsequently leading to the elevation of inflammatory markers, such as CRP [24, 25]. Similarly, elevated CRP levels have previously been associated with HTN, another frequently documented comorbidity of PsA [26, 27]. Indeed, inflammation has been proven to have a crucial role in HTN development, with elevated CRP levels constituting a strong predictor for elevated blood pressure and normal CRP levels associated with hypertension remission irrespective of treatment, baseline systolic blood pressure, and anthropometric improvements [26, 28]. Given the independent associations of elevated CRP with BMI and HTN, a compelling link with the metabolic syndrome (MetS) emerges [25, 29]. MetS is a cluster of risk factors for cardiovascular disease, stroke and diabetes mellitus type 2, which include insulin resistance, central obesity, HTN, and atherogenic dyslipidaemia, and it has been shown to be highly prevalent among PsA patients [30, 31]. The components of the syndrome, particularly obesity and insulin resistance, mediate a proinflammatory state via the secretion of cytokines such as IL-6 and TNFα, which is proven to be detrimental in the syndrome’s pathophysiology [25]. Therefore, both in the general population as well as in PsA patients, the MetS has been associated with inflammation, as seen by elevated levels of CRP [31, 32]. In our study, we demonstrated for the first time that an elevated CRP at diagnosis is associated with new bone formation of the small joints of the hands, an outcome observed in approximately half of our patients. Regarding the impact of CRP in radiographic damage, in a study by Haroon et al. [11] that examined the association of CRP at the first rheumatology visit with disease outcomes, PsA patients with elevated baseline CRP displayed worse long-term radiographic damage (peripheral joint erosions and sacroiliitis on radiographs), compared with those with normal CRP [11]. Similarly, a subanalysis of the ADEPT trial concluded that baseline CRP is an independent predictor of radiographic progression (defined as a change in modified total Sharp score ΔmTSS > 0.5) in PsA, especially in untreated patients [19]. CRP was also associated with greater radiographic progression by van der Heijde et al., who defined radiographic non-progression as a ≤5 increase from baseline modified total Sharp Score [18]. In our study, no association was found between CRP levels at diagnosis and radiology findings in the axis of the PsA patients enrolled. We also found that, at diagnosis, elevated CRP appeared to be associated with the existence of enthesitis. Enthesitis is a common feature of PsA [33, 34] and is recognized as one of the key drivers of D2M/TR disease [35], although its pathogenetic mechanism in the disease is not entirely understood [33]. PG E2 initiates the inflammatory process, possibly inducing an acute stress response and activating the IL-13–IL-23 pathway [33, 34]. IL-17, along with TNFα—both produced due to IL-23 signalling—are key amplifiers of entheseal inflammation, with IL-17 causing further production of inflammatory mediators, such as IL-6 [33, 34], but also CRP itself [36]. Therefore, this link between IL-17 and CRP production may underlie the association between enthesitis and elevated CRP in our study [33]. However, in a previous study, CRP levels were not associated with enthesitis in PsA patients, nor with the extent of entheseal disease [37]. The value of CRP has been debated in the field of PsA for a long time. A significant percentage of PsA patients with clinically active disease do not show elevated CRP levels, raising questions regarding the utility of this acute-phase reactant in disease monitoring [17]. Indeed, when comparing DAPSA and cDAPSA in disease monitoring, Gonçalves et al. [16], Proft et al. [13] and van Mens et al. [15] documented a near-perfect agreement between the two indices in disease activity categorization, with the last also noting that the proportion of patients in remission was similar between those who had increased serum CRP levels and those who did not. It has been hypothesized that the frequent observation of normal CRP levels in PsA patients could be attributed to the minimal role of IL-6 in PsA pathogenesis, as it is one of the most significant cytokines in CRP signalling [37]. Sokolova et al. [37] and Gialouri et al. [17] suggest that alternative serum markers that detect different inflammatory pathways and different sites of inflammation could be indicative of existent inflammation when CRP is not. The aforementioned points, coupled with the fact that in our study ∼80% of the patients in the ‘normal’ CRP group maintained normal levels at the time of assessment, support the possibility of distinct immunologic phenotypes within PsA, with ‘elevated’ CRP patients representing a potentially separate PsA subgroup. We acknowledge that this study has certain limitations. First, the cross-sectional design precludes causal inference, as does the model used for the multivariable analysis. Additionally, recall bias, missing data, and possibly inadequately controlled confounding variables are unavoidable due to the retrospective nature of the study. Nonetheless, in our study, <10% of the data was missing and all data was recorded in a predefined form with specific instructions given to the investigators. Patients with missing data were not included in the multivariable analyses. Selection bias is also a possibility, particularly in radiographic assessments, which were not performed systematically for all patients and were likely performed based on clinical indications. Also, no central reading of the x-rays was conducted, which may have led to a bias. Moreover, the findings for this study were collected in a specific electronic form that the investigators were asked to fill in. Another limitation is that, even though psoriasis was present in all patients included in the study, data on disease severity [Psoriasis Area and Severity Index (PASI) or BSA] were not sufficiently complete to be included in our analysis. Furthermore, we acknowledge that the ‘persistent disease’ definition includes CRP levels at the time of assessment, introducing potential overlap with CRP at diagnosis. However, the potential for circularity is limited, as CRP levels represent one component of a composite definition that includes multiple other variables. In addition, CRP in the ‘persistent disease’ definition refers to a measurement within the last 6 months prior to the time of assessment, and given that the follow-up time was shown to be 8.3 ± 7.2 years, it was not necessarily related to CRP at diagnosis. Finally, the longer follow-up time in the ‘elevated CRP’ group could increase the incidence of adverse outcomes. To partially account for this, it was included in the multivariable analysis. Also, we note that the mean time between PsA diagnosis and the conducting of hand x-rays showed no statistically significant difference between the two groups. This study also has multiple strengths. A major strength of this study is that it reflects a real-world cohort of patients with PsA, including individuals with diverse disease characteristics. The sample analysed was considerably large and derived from a multicentre registry. Furthermore, to our knowledge, this is the first study that has included EULAR’s definition of D2M and TR PsA. Importantly, the analysed population was divided by CRP levels at diagnosis, in treatment-naïve patients; hence, the potential confounding effect of immunomodulatory treatment is not present in the CRP measurements, allowing for a clearer assessment of the marker’s prognostic value. In conclusion, CRP levels at PsA diagnosis appear to have clinical significance, being associated with adverse outcomes, such as new bone formation and ‘persistent disease’. The levels of this acute-phase reactant at diagnosis could serve as an identifier of separate PsA subgroups with potentially different disease trajectories. Thus, given the clinical heterogeneity of PsA and the challenges it poses for treatment selection across multiple disease domains [7], this biomarker may contribute to improved risk stratification and a more personalized treatment approach, ultimately optimizing patient care. In this context, further research is warranted to define the prognostic utility of CRP in PsA and to determine its value as a biomarker for disease burden, treatment response, and long-term clinical outcomes. Institutional Review Board approval was provided by the Joint Rheumatology Program (‘Laiko Hospital’ No.: 780/2021) and by the local institutional boards of participating centers. All patients provided written informed consent. Supplementary Material Contributor Information Angeliki E Dimopoulou, Joint Academic Rheumatology Program, First Department of Propedeutic and Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece. Charalampos Papagoras, First Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece. Niki Kyriazi, Department of Rheumatology, Evangelismos Athens General Hospital, Athens, Greece. Sousana Gazi, Department of Rheumatology, KAT Hospital, Athens, Greece. Evangelia Mole, Department of Rheumatology, KAT Hospital, Athens, Greece. Michael Krikelis, Department of Rheumatology, KAT Hospital, Athens, Greece. Paraskevi V Voulgari, Department of Rheumatology, School of Health Sciences, Faculty of Medicine, University of Ioannina, Ioannina, Greece. Evripidis Kaltsonoudis, Department of Rheumatology, School of Health Sciences, Faculty of Medicine, University of Ioannina, Ioannina, Greece. Nikolaos Koletsos, Department of Rheumatology, School of Health Sciences, Faculty of Medicine, University of Ioannina, Ioannina, Greece. Pelagia Katsimpri, Department of Rheumatology, KAT Hospital, Athens, Greece. Dimitrios Boumpas, Joint Academic Rheumatology Program, 4th Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece. Dimitrios Katsifis-Nezis, Joint Academic Rheumatology Program, 4th Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece. Nikolaos Kougkas, 4th Department of Medicine, Aristotle University, Thessaloniki, Greece. Theodoros Dimitroulas, 4th Department of Medicine, Aristotle University, Thessaloniki, Greece. Petros P Sfikakis, Joint Academic Rheumatology Program, First Department of Propedeutic and Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece. Maria G Tektonidou, Joint Academic Rheumatology Program, First Department of Propedeutic and Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece. Konstantinos D Vassilakis, Joint Academic Rheumatology Program, First Department of Propedeutic and Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece. Dimitrios Bogdanos, Department of Rheumatology and Clinical Immunology, University of Thessaly, Larissa, Greece. Theodora Simopoulou, Department of Rheumatology and Clinical Immunology, University of Thessaly, Larissa, Greece. Christos Koutsianas, Joint Academic Rheumatology Program, Clinical Immunology–Rheumatology Unit, 2nd Department of Medicine and Laboratory, National and Kapodistrian University of Athens, School of Medicine, General Hospital of Athens “Hippokration”, Athens, Greece. Eugenia Mavrea, Joint Academic Rheumatology Program, Clinical Immunology–Rheumatology Unit, 2nd Department of Medicine and Laboratory, National and Kapodistrian University of Athens, School of Medicine, General Hospital of Athens “Hippokration”, Athens, Greece. Gkikas Katsifis, Rheumatology Clinic, Naval Hospital of Athens, Athens, Greece. Konstantinos Kottas, Rheumatology Clinic, Naval Hospital of Athens, Athens, Greece. Maria Konsta, Rheumatology Unit, Sismanoglio Hospital, Athens, Greece. Matthoula Tziafalia, Rheumatology Unit, Sismanoglio Hospital, Athens, Greece. Evangelia Kataxaki, Rheumatology Department, General Hospital Elefsinas Thriaseio, Athens, Greece. Eleni Kalavri, Department of Rheumatology, Asklepieion General Hospital, Athens, Greece. Kalliopi Klavdianou, Department of Rheumatology, Asklepieion General Hospital, Athens, Greece. Anastasios Karamanakos, Department of Rheumatology, Evangelismos Athens General Hospital, Athens, Greece. Ioannis Xynogalas, Department of Rheumatology, Evangelismos Athens General Hospital, Athens, Greece. Dimitrios Daoussis, Department of Rheumatology, Patras University Hospital, University of Patras Medical School, Patras, Greece. George Iliopoulos, Private Practice, Athens, Greece. Ilias Bournazos, Private Practice, Athens, Greece. Konstantinos Georganas, Private Practice, Athens, Greece. Dimos Patrikos, Private Practice, Athens, Greece. Dimitrios Vassilopoulos, Joint Academic Rheumatology Program, Clinical Immunology–Rheumatology Unit, 2nd Department of Medicine and Laboratory, National and Kapodistrian University of Athens, School of Medicine, General Hospital of Athens “Hippokration”, Athens, Greece. George E Fragoulis, Joint Academic Rheumatology Program, First Department of Propedeutic and Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece; School of Infection and Immunity, University of Glasgow, Glasgow, UK. Supplementary material Supplementary material is available at Rheumatology online. Data availability The Greek Rheumatology Society has the ownership of the data. These are available upon reasonable request to the corresponding author. Contribution statement Data Curation: all authors. Conceptualization: George E. Fragoulis. Formal analysis: Angeliki E. Dimopoulou, Niki Kyriazi. Methodology: GEF, Charalampos Papagoras, Dimitrios Vassilopoulos. Writing original draft: Angeliki E. Dimopoulou, Niki Kyriazi. Writing–review and editing: all authors. Supervision: George E. Fragoulis, Charalampos Papagoras, Dimitrios Vassilopoulos. Funding No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this manuscript. Disclosure statement: M.T. is an Associate Editor of Rheumatology. The other authors have declared no conflicts of interest. References Associated Data Supplementary Materials Data Availability Statement The Greek Rheumatology Society has the ownership of the data. These are available upon reasonable request to the corresponding author.